（文章来源：每日经济新闻） 每经AI快讯，11月9日，天臣医疗(688013.SH)发布公告，为保证回购股份方案顺利实施，公司拟将回购 价格上限由不超过人民币28.03元/股(含)调整为不超过人民币70.00元/股(含)。除调整回购股份价格上限 外，本次回购股份方案的其他内容不变。 ...

智通财经APP讯，天臣医疗(688013.SH)发布公告，为保证回购股份方案顺利实施，公司拟将回购价格 上限由不超过人民币28.03元/股(含)调整为不超过人民币70.00元/股(含)。除调整回购股份价格上限外， 本次回购股份方案的其他内容不变。 ...

Core Viewpoint - Tianchen Medical (688013.SH) has announced an adjustment to its share repurchase plan, increasing the maximum repurchase price from RMB 28.03 per share to RMB 70.00 per share while keeping other aspects of the plan unchanged [1] Group 1 - The company aims to ensure the smooth implementation of its share repurchase plan [1] - The adjustment in the maximum repurchase price reflects the company's commitment to enhancing shareholder value [1]

智通财经APP讯，天臣医疗(688013.SH)发布公告，为保证回购股份方案顺利实施，公司拟将回购价格 上限由不超过人民币28.03元/股(含)调整为不超过人民币70.00元/股(含)。除调整回购股份价格上限外， 本次回购股份方案的其他内容不变。 ...

重要内容提示： 为保证回购股份方案顺利实施，天臣国际医疗科技股份有限公司（以下 简称"公司"）拟将回购价格上限由不超过人民币28.03元/股（含）调整为不超过 人民币70.00元/股（含）。 除调整回购股份价格上限外，本次回购股份方案的其他内容不变。 本次调整回购股份价格上限的事项已经公司第二届董事会第三十一次会 议审议通过，无需提交股东会审议。 一、回购股份的基本情况 2023年12月27日，公司召开第二届董事会第十次会议，审议通过了《关于< 公司以集中竞价交易方式回购公司股份的方案>的议案》，同意公司以集中竞价 交易方式回购公司股份，拟用于实施员工持股计划或股权激励，回购资金总额不 低于人民币1,800万元（含），不超过人民币3,600万元（含），回购价格不超过 人民币30.00元/股，回购期限自公司董事会审议通过回购方案之日起12个月内。 具体内容详见公司于2023年12月28日在上海证券交易所网站（www.sse.com.cn） 上披露的《天臣国际医疗科技股份有限公司关于以集中竞价交易方式回购公司股 份的回购报告书》（公告编号：2023-048）。 2024年7月9日，公司召开第二届董事会第十五次会议 ...

Core Viewpoint - The medical device sector experienced a slight decline of 0.31% on November 6, with Danaher Biomedical leading the losses, while the overall market indices showed gains, with the Shanghai Composite Index up by 0.97% and the Shenzhen Component Index up by 1.73% [1][2]. Group 1: Market Performance - The Shanghai Composite Index closed at 4007.76, increasing by 0.97% [1]. - The Shenzhen Component Index closed at 13452.42, increasing by 1.73% [1]. - The medical device sector saw a net outflow of 638 million yuan from major funds, while retail investors contributed a net inflow of 446 million yuan [2][3]. Group 2: Individual Stock Performance - Hualan Co., Ltd. (301093) saw a significant increase of 8.53%, closing at 44.00 yuan with a trading volume of 67,500 shares and a transaction value of 293 million yuan [1]. - Danaher Biomedical (920009) led the declines with a drop of 4.69%, closing at 83.50 yuan and a trading volume of 24,900 shares, resulting in a transaction value of 206 million yuan [2]. - Other notable gainers included Furuida (300049) with a 4.32% increase and a closing price of 74.56 yuan, and Kangzhong Medical (688607) with a 3.04% increase, closing at 29.81 yuan [1][2]. Group 3: Fund Flow Analysis - Major funds showed a net outflow in several stocks, including Furuida with a net outflow of 23.99 million yuan, while retail investors showed a net inflow of 25.27 million yuan [3]. - Dongfulong (300171) experienced a net inflow of 21.17 million yuan from major funds, indicating positive sentiment towards the stock [3]. - The overall trend indicates a mixed sentiment in the medical device sector, with some stocks attracting retail interest despite the overall outflow from major funds [2][3].

Core Points - Tianchen Medical announced that the board of directors will postpone its re-election, and the terms of the board's specialized committees and senior management will be extended accordingly [1]

证券代码：688013 证券简称：天臣医疗 公告编号：2025-061 天臣国际医疗科技股份有限公司 关于董事会延期换届及独立董事任期届满 的提示性公告 公司现任独立董事陆志安先生、范明先生、金文龙先生的任期于2025年11 月9日届满且连任时间满六年，即将任期届满离任。鉴于各位独立董事任期届满 离任将导致公司独立董事人数少于董事会成员的三分之一，根据《上市公司独立 董事管理办法》和《公司章程》等相关规定，在董事会换届工作完成以前，陆志 安先生、范明先生、金文龙先生将按照法律法规等相关规定，继续履行独立董事 及相关董事会专门委员会委员职责，直至公司股东会选举产生新的独立董事。 1 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、公司董事会延期换届的情况 天臣国际医疗科技股份有限公司（以下简称"公司"）第二届董事会将于2025 年11月9日任期届满。鉴于相关换届工作尚在积极筹备中，为保证公司董事会相 关工作的连续性及稳定性，公司董事会将延期换届，董事会各专门委员会、高级 管理人员的任期将相应顺延。 在公司董事会换届选举工 ...

Summary of Key Points Core Viewpoint - Tianchen Medical (688013) has been actively repurchasing shares, with a total of 2,505,324 shares bought back, representing 3.09% of the total share capital, and a total expenditure of approximately 42.5 million yuan as of October 31, 2025 [1][3]. Trading Information - On October 31, 2025, Tianchen Medical's stock closed at 51.69 yuan, up 2.38%, with a turnover rate of 2.37% and a trading volume of 19,200 shares, resulting in a transaction value of 99.12 million yuan [1]. - The net outflow of funds from major investors was 360.49 thousand yuan, accounting for 3.64% of the total transaction value, while retail investors saw a net inflow of 1,619.33 thousand yuan, making up 16.34% of the total transaction value [1][3]. Company Announcements - Tianchen Medical initiated a share repurchase program on December 27, 2023, with an original plan to repurchase between 18 million yuan and 36 million yuan. This amount was later adjusted to a range of 46 million yuan to 80 million yuan, with the repurchase period extended to December 26, 2025 [1]. - The repurchased shares are intended for employee stock ownership plans or equity incentives, and the repurchase price ranged from 11.87 yuan to 21.00 yuan per share [1].

Core Points - Tianchen Medical (688013) closed at 51.69 yuan on October 31, 2025, down 7.13% from last week's 55.66 yuan [1] - The company's current market capitalization is 4.195 billion yuan, ranking 84th out of 126 in the medical device sector and 3768th out of 5163 in the A-share market [1] Company Announcements - Tianchen Medical initiated a share buyback on December 27, 2023, with an original plan to repurchase between 18 million yuan and 36 million yuan, which was later adjusted to a total buyback amount of 46 million yuan to 80 million yuan, extending the deadline to December 26, 2025 [2] - The funding sources for the buyback include self-owned funds and a special loan not exceeding 34.65 million yuan [2] - As of October 31, 2025, the company has repurchased a total of 2,505,324 shares, accounting for 3.09% of the total share capital, with a total expenditure of approximately 42.4989 million yuan, at a buyback price range of 11.87 yuan to 21.00 yuan per share [2][3] - No share buyback transactions were conducted in October 2025 [3]